Published in NMR Biomed on October 01, 2005
Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine (2012) 1.94
Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev (2010) 1.88
Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.73
Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine (2011) 1.72
Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging. Nat Med (2012) 1.53
Magnetic cell labeling of primary and stem cell-derived pig hepatocytes for MRI-based cell tracking of hepatocyte transplantation. PLoS One (2015) 1.40
Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One (2009) 1.36
Imaging stem cells implanted in infarcted myocardium. J Am Coll Cardiol (2006) 1.28
Optimization and validation of FePro cell labeling method. PLoS One (2009) 1.19
Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: discrimination of viable from lysed cells. Magn Reson Med (2009) 1.17
Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond) (2009) 1.15
In Vivo Cellular Imaging for Translational Medical Research. Curr Med Imaging Rev (2009) 1.12
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med (2013) 1.07
Peroxidase-mediated biodegradation of carbon nanotubes in vitro and in vivo. Adv Drug Deliv Rev (2013) 1.07
Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human hematopoietic stem cells. Stem Cells (2007) 1.04
Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med (2009) 1.03
Human cord blood-derived AC133+ progenitor cells preserve endothelial progenitor characteristics after long term in vitro expansion. PLoS One (2010) 1.02
Magnetic poly(lactide-co-glycolide) and cellulose particles for MRI-based cell tracking. Magn Reson Med (2011) 1.02
Imaging cerebral gene transcripts in live animals. J Neurosci (2007) 1.02
Gene expression profiling reveals early cellular responses to intracellular magnetic labeling with superparamagnetic iron oxide nanoparticles. Magn Reson Med (2010) 1.02
Engineered biocompatible nanoparticles for in vivo imaging applications. J Am Chem Soc (2010) 1.00
Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo. FASEB J (2008) 0.99
A general mechanism for intracellular toxicity of metal-containing nanoparticles. Nanoscale (2014) 0.98
Biocompatible and pH-sensitive PLGA encapsulated MnO nanocrystals for molecular and cellular MRI. ACS Nano (2011) 0.97
Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage (2010) 0.95
Stem cell tracking using iron oxide nanoparticles. Int J Nanomedicine (2014) 0.95
Convertible manganese contrast for molecular and cellular MRI. Magn Reson Med (2008) 0.94
Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene Ther (2012) 0.93
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev (2015) 0.92
Nanoparticles based stem cell tracking in regenerative medicine. Theranostics (2013) 0.91
Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy. Theranostics (2013) 0.91
The cytotoxicity of polycationic iron oxide nanoparticles: common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. J Nanobiotechnology (2012) 0.91
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet (2011) 0.90
Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering. PLoS One (2014) 0.90
N-hexanoyl chitosan stabilized magnetic nanoparticles: Implication for cellular labeling and magnetic resonance imaging. J Nanobiotechnology (2008) 0.89
Reduced adhesion of Staphylococcus aureus to ZnO/PVC nanocomposites. Int J Nanomedicine (2013) 0.89
Effects of ferumoxides-protamine sulfate labeling on immunomodulatory characteristics of macrophage-like THP-1 cells. PLoS One (2008) 0.87
Serial monitoring of endogenous neuroblast migration by cellular MRI. Neuroimage (2011) 0.87
Simple SPION incubation as an efficient intracellular labeling method for tracking neural progenitor cells using MRI. PLoS One (2013) 0.87
Ferritin enhances SPIO tracking of C6 rat glioma cells by MRI. Mol Imaging Biol (2011) 0.87
Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. NMR Biomed (2011) 0.85
Cell labeling with magnetic nanoparticles: opportunity for magnetic cell imaging and cell manipulation. J Nanobiotechnology (2013) 0.84
Mechanism of cellular uptake and impact of ferucarbotran on macrophage physiology. PLoS One (2011) 0.83
Intracellular Delivery of siRNA by Polycationic Superparamagnetic Nanoparticles. J Drug Deliv (2012) 0.82
Comparative in vitro study on magnetic iron oxide nanoparticles for MRI tracking of adipose tissue-derived progenitor cells. PLoS One (2014) 0.81
Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging. J Mater Chem B Mater Biol Med (2014) 0.81
Nanoparticle-labeled stem cells: a novel therapeutic vehicle. Clin Pharmacol (2010) 0.81
Stem Cell Tracking with Nanoparticles for Regenerative Medicine Purposes: An Overview. Stem Cells Int (2015) 0.80
Effects of Mesoporous Silica Coating and Post-Synthetic Treatment on the Transverse Relaxivity of Iron Oxide Nanoparticles. Chem Mater (2013) 0.79
Nanomedicine strategies for treatment of secondary spinal cord injury. Int J Nanomedicine (2015) 0.79
Selective antibacterial effects of mixed ZnMgO nanoparticles. J Nanopart Res (2013) 0.78
Release activation of iron oxide nanoparticles: (REACTION) a novel environmentally sensitive MRI paradigm. Magn Reson Med (2011) 0.78
Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain. NMR Biomed (2011) 0.78
Human-like collagen protein-coated magnetic nanoparticles with high magnetic hyperthermia performance and improved biocompatibility. Nanoscale Res Lett (2015) 0.78
Biodegradable, polymer encapsulated, metal oxide particles for MRI-based cell tracking. Magn Reson Med (2014) 0.77
Dual-modality, fluorescent, PLGA encapsulated bismuth nanoparticles for molecular and cellular fluorescence imaging and computed tomography. Nanoscale (2014) 0.77
In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magn Reson Med (2011) 0.77
Effects of supermagnetic iron oxide labeling on the major functional properties of human mesenchymal stem cells from multiple sclerosis patients. Int J Stem Cells (2010) 0.76
Physiological Remediation of Cobalt Ferrite Nanoparticles by Ferritin. Sci Rep (2017) 0.75
Mechanistic understanding of toxicity from nanocatalysts. Int J Mol Sci (2014) 0.75
Recent progress on magnetic nanoparticles for magnetic hyperthermia. Prog Biomater (2016) 0.75
Transferrin receptor expression in iron oxide-labeled mesenchymal stem cells. Radiology (2008) 0.75
Pure and multi metal oxide nanoparticles: synthesis, antibacterial and cytotoxic properties. J Nanobiotechnology (2016) 0.75
Molecular Imaging with MRI: Potential Application in Pancreatic Cancer. Biomed Res Int (2015) 0.75
Targeting T1 and T2 dual modality enhanced magnetic resonance imaging of tumor vascular endothelial cells based on peptides-conjugated manganese ferrite nanomicelles. Int J Nanomedicine (2016) 0.75
Advances in biodegradable nanomaterials for photothermal therapy of cancer. Cancer Biol Med (2016) 0.75
Visible-light-sensitive titanium dioxide nanoplatform for tumor-responsive Fe2+ liberating and artemisinin delivery. Oncotarget (2017) 0.75
Assessing cell-nanoparticle interactions by high content imaging of biocompatible iron oxide nanoparticles as potential contrast agents for magnetic resonance imaging. Sci Rep (2017) 0.75
Toxicity of Nanoparticles on the Reproductive System in Animal Models: A Review. Front Pharmacol (2017) 0.75
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood (2004) 4.66
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med (2006) 3.81
Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology (2003) 3.72
Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology (2003) 3.71
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed (2005) 2.02
In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab (2002) 1.99
Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol (2008) 1.87
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Cellular magnetic resonance imaging: current status and future prospects. Expert Rev Med Devices (2006) 1.71
Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells (2005) 1.61
In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther (2004) 1.61
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol (2005) 1.60
Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed (2006) 1.58
Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol (2008) 1.56
Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation (2003) 1.55
Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging. Nat Med (2012) 1.53
Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol (2002) 1.53
Craniotomy: true sham for traumatic brain injury, or a sham of a sham? J Neurotrauma (2011) 1.49
Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med (2005) 1.48
Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain (2003) 1.43
In vitro model of bromodeoxyuridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. Stem Cells (2008) 1.41
Neurite beading is sufficient to decrease the apparent diffusion coefficient after ischemic stroke. Proc Natl Acad Sci U S A (2010) 1.40
Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J (2008) 1.36
Susceptibility gradient mapping (SGM): a new postprocessing method for positive contrast generation applied to superparamagnetic iron oxide particle (SPIO)-labeled cells. Magn Reson Med (2008) 1.28
Temporal dynamics of the BOLD fMRI impulse response. Neuroimage (2004) 1.28
Viral capsids as MRI contrast agents. Magn Reson Med (2007) 1.28
Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol (2006) 1.24
Cellular MRI and its role in stem cell therapy. Regen Med (2008) 1.23
Examining brain microstructure using structure tensor analysis of histological sections. Neuroimage (2012) 1.21
Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness". PLoS One (2010) 1.20
Optimization and validation of FePro cell labeling method. PLoS One (2009) 1.19
In vivo MRI using positive-contrast techniques in detection of cells labeled with superparamagnetic iron oxide nanoparticles. NMR Biomed (2008) 1.17
Macrophagic and microglial responses after focal traumatic brain injury in the female rat. J Neuroinflammation (2014) 1.14
In vivo transfer of intracellular labels from locally implanted bone marrow stromal cells to resident tissue macrophages. PLoS One (2009) 1.12
In Vivo Cellular Imaging for Translational Medical Research. Curr Med Imaging Rev (2009) 1.12
Magnetic tagging of therapeutic cells for MRI. J Nucl Med (2009) 1.11
Ultrashort T2* relaxometry for quantitation of highly concentrated superparamagnetic iron oxide (SPIO) nanoparticle labeled cells. Magn Reson Med (2009) 1.09
Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties. Nano Lett (2009) 1.08
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med (2013) 1.07
Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol (2004) 1.07
Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med (2009) 1.03
Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J Neurol Sci (2004) 1.02
EPI-BOLD fMRI of human motor cortex at 1.5 T and 3.0 T: sensitivity dependence on echo time and acquisition bandwidth. J Magn Reson Imaging (2004) 1.00
Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. Stem Cells (2012) 1.00
MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain. Magn Reson Med (2003) 0.98
Effect of human stem cells labeled with ferumoxides-poly-L-lysine on hematologic and biochemical measurements in rats. Radiology (2005) 0.96
Imaging approaches for the study of cell-based cardiac therapies. Nat Rev Cardiol (2009) 0.96
Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain (2005) 0.95
Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI. PLoS One (2010) 0.93
Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis (2011) 0.92
Imaging of spontaneous ventriculomegaly and vascular malformations in Wistar rats: implications for preclinical research. J Neuropathol Exp Neurol (2014) 0.91
Loss of interhemispheric inhibition in patients with multiple sclerosis is related to corpus callosum atrophy. Exp Brain Res (2006) 0.91
P22 viral capsids as nanocomposite high-relaxivity MRI contrast agents. Mol Pharm (2012) 0.91
In vivo detection of embryonic stem cell-derived cardiovascular progenitor cells using Cy3-labeled Gadofluorine M in murine myocardium. JACC Cardiovasc Imaging (2009) 0.90
Synthesis of superparamagnetic nanotubes as MRI contrast agents and for cell labeling. Nanomedicine (Lond) (2008) 0.90
Synthesis of Complexable Fluorescent Superparamagnetic Iron Oxide Nanoparticles (FL SPIONs) and Cell Labeling for Clinical Application. Adv Mater (2008) 0.90
Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci Lett (2008) 0.89
Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. PLoS One (2011) 0.88
Effects of indomethacin on cerebral blood flow at rest and during hypercapnia: an arterial spin tagging study in humans. J Magn Reson Imaging (2002) 0.88
Monitoring stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents. Acad Radiol (2002) 0.86
Pulsed arterial spin labeling: comparison of multisection baseline and functional MR imaging perfusion signal at 1.5 and 3.0 T: initial results in six subjects. Radiology (2002) 0.85
The evolution of traumatic brain injury in a rat focal contusion model. NMR Biomed (2012) 0.84
Magnetically-labeled sensitized splenocytes to identify glioma by MRI: a preliminary study. Magn Reson Med (2007) 0.84
MRI of mouse models of neurological disorders. NMR Biomed (2007) 0.84
Pulsed focused ultrasound pretreatment improves mesenchymal stromal cell efficacy in preventing and rescuing established acute kidney injury in mice. Stem Cells (2015) 0.83
Rapid spectrophotometric technique for quantifying iron in cells labeled with superparamagnetic iron oxide nanoparticles: potential translation to the clinic. Contrast Media Mol Imaging (2012) 0.83
Cyclooxygenase-2 or tumor necrosis factor-α inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle. Stem Cells (2015) 0.82
Quantitative T2* imaging of metastatic human breast cancer to brain in the nude rat at 3 T. NMR Biomed (2010) 0.81
Effects of long-term hypoxia and pro-survival cocktail in bone marrow-derived stromal cell survival. Stem Cells Dev (2013) 0.81